Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 6/20 | 0.79 |
| ▸ | MAOB known ✓ | P27338 | 6/20 | 0.79 |
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 0.79 |
| ▸ | SDHA | P31040 | 2/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | CALML3 | P27482 | 1/20 | 0.79 |
| ▸ | F10 | P00742 | 7/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4689051 | 1.00 | MAOA (0.79) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL1894257 | 0.99 | MAOA (0.80) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL1498511 | 0.99 | MAOA (0.80) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL5818098 | 0.95 | MAOA (0.75) | MAOAMAOBPTGS1SDHALMNA | |
| Phosphonic Acid SCHEMBL5325175 | 0.95 | MAOB (0.75) | MAOAMAOBPTGS1SDHALMNA | |
| Trifluoroacetic Acid SCHEMBL5943313 | 0.94 | MAOB (0.73) | MAOAMAOBPTGS1SDHALMNA | |
| Trifluoroacetic Acid SCHEMBL6509850 | 0.94 | MAOB (0.73) | MAOAMAOBPTGS1SDHALMNA | |
| Trifluoroacetic Acid SCHEMBL5727900 | 0.94 | MAOB (0.73) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL10151522 | 0.93 | MAOA (0.80) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL4163701 | 0.92 | MAOA (0.70) | MAOAMAOBPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3328856-A2 | ANTIBACTERIAL THERAPEUTICS AND PROPHYLACTICS | Vyome Biosciences Pvt. Ltd. (IN) | 2018-06-06 | — | — | EP | disclosed |
| WO-2017017631-A2 | ANTIBACTERIAL THERAPEUTICS AND PROPHYLACTICS | VYOME BIOSCIENCES PVT. LTD. (IN) | 2017-02-02 | — | — | WO | disclosed |
| EP-1114819-B1 | Process to prepare oxazolidinones | PHARMACIA & UPJOHN CO LLC (US) | 2008-01-09 | — | — | EP | disclosed |
| CN-1319952-C | Method for preparing oxazolidone amine | PHARMACIA & UPJOHN CO LLC (US) | 2007-06-06 | — | — | CN | disclosed |
| US-20070060558-A1 | Hybrid molecules QA where Q is an aminoquinoline and A is an antibiotic residue, the synthesis and uses thereof as antibacterial agents | PALUMED S.A. (FR) | 2007-03-15 | — | — | US | disclosed |
| US-20060293307-A1 | Oxazolidinone derivatives as antimicrobials | RANBAXY LABORATORIES LIMITED (IN) | 2006-12-28 | — | — | US | disclosed |
| EP-1615917-A1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | Pharmacia & Upjohn Company LLC (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004087697-A1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-10-14 | — | — | WO | disclosed |
| CN-1167701-C | Process for preparing oxazolidone amines | �������Ŷ���Լ��������˾ | 2004-09-22 | — | — | CN | disclosed |
| CN-1496983-A | Method for preparing oxazolidone amine | �������Ŷ���Լ��������˾ | 2004-05-19 | — | — | CN | disclosed |
| CN-1381454-A | Process for preparing oxazolidone amines | UPJOHN CO (US) | 2002-11-27 | — | — | CN | disclosed |
| CN-1082953-C | Process for preparing oxazolidinones | UPJOHN CO (US) | 2002-04-17 | — | — | CN | disclosed |
| EP-1114819-A1 | Process to prepare oxazolidinones | PHARMACIA & UPJOHN COMPANY (US) | 2001-07-11 | — | — | EP | disclosed |
| CN-1215393-A | Process for preparing oxazolidinones | UPJOHN CO (US) | 1999-04-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060558-A1 | Hybrid molecules QA where Q is an aminoquinoline and A is an antibiotic residue, the synthesis and uses thereof as antibacterial agents | QARS1, QPCT, QTRT2 | MAOA 1016/4885MAOB 1323/4885PTGS1 3142/4885 |
| US-20060293307-A1 | Oxazolidinone derivatives as antimicrobials | OXA1L, PDK4, SDHA | MAOA 1568/4885MAOB 1976/4885PTGS1 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.